Idorsia Pharmaceuticals Ltd: Idorsia and Simcere enter into

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland & Nanjing, China - November 16, 2022 Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the discovery, development and

Related Keywords

Germany , Japan , United States , Hong Kong , United Kingdom , Allschwil , Switzerland General , Switzerland , Italy , China , Canada , Nanjing , Jiangsu , Macau , Chinese , Great Britain , American , Swiss , Andrewc Weiss , Jinsheng Ren , Jean Paul Clozel , J Clin Pharmacol , Idorsia Ltd , American Psychiatric Association , Head Of Investor Relations Corporate Communications , Simcere Pharmaceutical Group , European Commission Decision Reliance Procedure , European Commission , Drug Administration , Simcere Pharmaceutical Group Ltd , Swiss Exchange , Regulatory Agency , National Medical Products Administration , Idorsia Pharmaceuticals Ltd , Health Canada , Central Nervous System , Greater China , Mainland China , Paul Clozel , Chief Executive Officer , Lancet Neurology , Full Prescribing Information , Medication Guide , European Commission Decision Reliance , Product Characteristics , Insomnia Daytime Symptoms , Impacts Questionnaire , Statistical Manual , Mental Disorders , Discov Today Dis , Clin Sleep , Pharmaceutical Group Limited , Vice President , Investor Relations , Pharmaceuticals Ltd , Idorsia , Pharmaceuticals , Simcere , Winter , Icensing , Agreement , Daridorexant ,